Funding for this research was provided by:
European Regional Development Fund
Ministerie van Economische Zaken (grant 31O.041)
Stichting De Weijerhorst
CARIM School for Cardiovascular Diseases, Universiteit Maastricht
Stichting Sint Annadal
the Pearl String Initiative Diabetes
Health Foundation Limburg
Novo Nordisk Farma B.V.
Sanofi-Aventis Netherlands B.V.
Received: 20 March 2020
Accepted: 8 June 2020
First Online: 15 June 2020
Ethics approval and consent to participate
: The study has been approved by the institutional medical ethical committee (Medisch Ethische Toetsingscommissie, Maastricht University) (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent.
: Not applicable.
: PL, MV, RH, CK, AK, MS, and CS have nothing to disclose. Dr. HPBLR reports unrestricted research grants from Roche Diagnostics, Vifor and Novartis and serves as member of the advisory board of Roche Diagnostics, Vifor and Novartis outside the submitted work.